Hypertension. Telmisartan tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Telmisartan (Micardis) is an ARB prescribed for the treatment of high blood pressure and the prevention of heart attack, stroke, and cardiovascular events in patients at risk. Background. A reduction in estimated glomerular filtration rate (eGFR), and/or the presence of proteinuria, are the predominant manifestations of chronic kidney disease (CKD), which is common in the elderly population. The heart pumps blood through the body via large blood vessels known as the arteries. Hypertension means the pressure (or tension) in the arteries is elevated. Introduction. Chronic kidney disease is a general term for heterogeneous disorders affecting the structure and function of the kidney. The variation in disease expression is related partly to cause and pathology, severity, and rate of progression. KEY POINTS. Albuminuria is best measured by the albumin-to-creatinine ratio. In several studies, albuminuria has been independently associated with a higher risk of death, cardiovascular events, heart failure, stroke, and progression of chronic kidney disease. Telmisartan oral tablet is available as both a generic and brand-name drug. Brand name: Micardis. Telmisartan only comes as a tablet you take by mouth. Description and Brand Names. Drug information provided by: IBM Micromedex. US Brand Name. Micardis; Descriptions. Telmisartan is used alone or together with other medicines to treat high blood pressure (hypertension). Telmisartan; Clinical data; Pronunciation / t ɛ l m ɪ ˈ s ɑːr t ən / Trade names: Micardis, Actavis, others. 2-(4- [4-Methyl-6-(1-methyl-1H-1,3-benzodiazol-2-yl)-2-propyl-1H-1,3-benzodiazol-1-yl]methyl phenyl)benzoic acid INDICATIONS. MICARDIS HCT (telmisartan and hydrochlorothiazide) is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.